PBAC's latest decision on Olodaterol: Not recommended (2014). Considered for Maintenance bronchodilator treatment of chronic obstructive pulmonary disease (COPD) in patients with a history of significant symptoms despite currently receiving regular long-acting muscarinic antagonist therapy.
PBAC outcome
Not recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Adult patients with chronic obstructive pulmonary disease with a history of significant symptoms despite currently receiving regular long-acting muscarinic antagonist therapy.
Cost-minimisation analysis; no ICER calculated by design.
Why PBAC said no
Reasons cited in the latest PSD: claim of non-inferior comparative effectiveness compared to indacaterol not adequately supported by data, inferior to indacaterol as monotherapy based on indirect comparison, change in trough FEV1 approximately lower with olodaterol compared to indacaterol